Middle East & Africa Antibody Drug Conjugates Market Overview, Growth, Trends, Analysis, Research Report (2023-2031)

The Middle East and Africa Antibody Drug Conjugates Market size is expected to reach US$ 314.4 Million by 2031 from US$ 70.4 Million in 2023. The market is estimated to record a CAGR of 20.6% from 2023 to 2031.

Executive Summary and Middle East and Africa Antibody Drug Conjugates Market Analysis:

The Middle East & Africa antibody drug conjugates market is segmented into the UAE, South Africa, Saudi Arabia, and the Rest of Middle East & Africa. Government initiatives to strengthen pharmaceutical development and rising cases of cancer are a few factors propelling the market in this region. The Middle East & Africa antibody-drug conjugates (ADC) market is primarily driven by the rising incidence of cancer, particularly in aging populations. Advancements in ADC technology and ongoing research boost treatment efficacy, making these therapies more attractive for oncology treatments. Strategic collaborations and partnerships between biopharmaceutical companies also play a significant role in accelerating ADC development. Additionally, increasing healthcare investments and the establishment of local biopharmaceutical infrastructure in countries like Saudi Arabia contribute to market growth.

Middle East & Africa Antibody Drug Conjugates Market: Strategic Insights

Middle East and Africa Antibody Drug Conjugates Market Segmentation Analysis:

• By Technology, the Middle East and Africa Antibody Drug Conjugates Market is segmented into Cleavable Linker and Non-cleavable Linker. Cleavable Linker held the largest share of the market in 2023.
• By Application, the Middle East and Africa Antibody Drug Conjugates Market is segmented into Blood Cancer, Brain Cancer, Breast Cancer, Ovarian Cancer, Lung Cancer, and Others. Breast Cancer held the largest share of the market in 2023.
• By Target, the Middle East and Africa Antibody Drug Conjugates Market is segmented into HER2, CD22, CD30, and Others. HER2 held the largest share of the market in 2023.
• By Distribution Channel, the Middle East and Africa Antibody Drug Conjugates Market is segmented into Retail Pharmacies, Hospital Pharmacies, and Online Pharmacies. Hospital Pharmacies held the largest share of the market in 2023.

Middle East & Africa Antibody Drug Conjugates Market Players Density: Understanding Its Impact on Business Dynamics

The Middle East & Africa Antibody Drug Conjugates Market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.

Middle East and Africa Antibody Drug Conjugates Market Outlook

The expansion into new indications is creating significant opportunities in the antibody-drug conjugates market. As antibody-drug conjugates are primarily designed to deliver cytotoxic agents directly to cancer cells while sparing healthy tissues, their ability to target specific tumor-associated antigens makes them highly versatile. This versatility allows for exploring antibody-drug conjugate applications beyond their initial indications, i.e., hematological malignancies and certain solid tumors.

Many cancers currently lack adequate treatment options, and introducing antibody-drug conjugates targeting new biomarkers can provide innovative therapies for these challenging conditions. For instance, antibody-drug conjugates are being investigated for treating cancers such as breast, lung, and bladder cancers, where traditional therapies may not yield satisfactory results. Additionally, the collaboration between pharmaceutical companies and research institutions fosters innovation in antibody-drug conjugate development. These partnerships often focus on identifying novel targets and optimizing linker technologies to enhance the efficacy and safety profiles of conjugates. Moreover, with the discovery and validation of new targets, antibody-drug conjugates are being further investigated for their potential utilization in the treatment of a broader range of cancer types. In July 2025, the Journal of the Egyptian National Cancer Institute published a study on Patritumab Deruxtecan, a HER3-directed ADC, in EGFR-mutant non-small cell lung cancer (NSCLC) after resistance to EGFR-TKIs. This marks a shift in using ADCs for lung cancer, moving beyond the usual areas like breast cancer. The trial reported a 39% response rate, showing its potential for treatment. Egypt’s role highlights progress in precision oncology in the region.

By addressing unmet medical needs, benefiting from favorable regulatory conditions, capitalizing on the rising prevalence of cancer, and fostering collaborative innovation, antibody-drug conjugates are poised to play a pivotal role in the future of targeted cancer therapies. Thus, an expansion into new indications presents a wealth of opportunities for the antibody-drug conjugates market.

Middle East and Africa Antibody Drug Conjugates Market Country Insights

By country, the Middle East and Africa Antibody Drug Conjugates Market is segmented into South Africa, Saudi Arabia, the United Arab Emirates, and the Rest of Middle East and Africa. Saudi Arabia held the largest share in 2023.

The rising prevalence of breast cancer is driving the adoption of breast cancer therapeutics in South Africa. As per Risk factors for breast cancer among women in Ekurhuleni Metropolitan Municipality, Gauteng province of South Africa, a study published in 2023, breast cancer is a common cancer among women in the country, with an age-standardized incidence rate of 52.6. In 2020, breast cancer accounted for 23% of all cancers in women. The increasing incidence of cancer in South Africa is contributing to a higher demand for effective treatment options, including antibody-drug conjugates. Antibody-drug conjugates are widely preferred due to their targeted approach, which can enhance patient outcomes while reducing side effects. Brentuximab vedotin for refractory Hodgkin lymphoma and Ado-trastuzumab emtansine for relapsed metastatic HER2+ breast cancer are a few of the government-approved therapies available in South Africa. Also, the presence of leading players, such as Pfizer, AstraZeneca, and Gilead Sciences, Inc., is fueling the growth of the antibody-drug conjugates market in South Africa. These companies employ various growth strategies to increase their market position, such as partnerships, agreements, collaborations, new product launches, regional expansions, mergers and acquisitions.

Middle East and Africa Antibody Drug Conjugates Market Company Profiles

Some of the key players operating in the market include GSK Plc, F. Hoffmann-La Roche Ltd, Pfizer Inc, Bristol-Myers Squibb Co, Johnson & Johnson, Takeda Pharmaceutical Co Ltd, AstraZeneca Plc, Astellas Pharma Inc, AbbVie Inc, Merck KGaA, Gilead Sciences Inc, BioNTech SE, Daiichi Sankyo Co Ltd, RemeGen Co Ltd, and ADC Therapeutics SA.

These players are adopting various strategies such as expansion, product innovation, and mergers and acquisitions to provide innovative products to their consumers and increase their market share.

Middle East and Africa Antibody Drug Conjugates Market Research Methodology

The following methodology has been followed for the collection and analysis of data presented in this report:

Secondary Research

The research process begins with comprehensive secondary research, utilizing internal and external sources to gather qualitative and quantitative data for each market. Commonly referenced secondary research sources include, but are not limited to:

• Company websites, annual reports, financial statements, broker analyses, and investor presentations
• Industry trade journals and other relevant publications
• Government documents, statistical databases, and market reports
• News articles, press releases, and webcasts specific to companies operating in the market

Note:

Primary Research

The Insight Partners conducts a significant number of primary interviews each year with industry stakeholders and experts to validate its data analysis and gain valuable insights. These research interviews are designed to:

• Validate and refine findings from secondary research
• Enhance the expertise and market understanding of the analysis team
• Gain insights into market size, trends, growth patterns, competitive dynamics, and future prospects

Primary research is conducted via email interactions and telephone interviews, encompassing various markets, categories, segments, and sub-segments across different regions. Participants typically include:

• Industry stakeholders: Vice Presidents, Business Development Managers, Market Intelligence Managers, and National Sales Managers
• External experts: Valuation specialists, research analysts, and key opinion leaders with industry-specific expertise